Biogen, Inc. NASDAQ: BIIB leki neurologiczne

[slayer74]

wykres
https://finance.yahoo.com/chart/biib?ltr=1
https://stockcharts.com/h-sc/ui?s=biib

Biogen, Inc. (dawniej Biogen Idec) NASDAQ: BIIB odkrywa, opracowuje i zapewnia pacjentom na całym świecie dostęp do innowacyjnych terapii dla osób z poważnymi schorzeniami neurologicznymi i neurodegeneracyjnymi. Biogen opracowuje, produkuje i komercjalizuje lekarstwa wykorzystywane przede wszystkim w terapiach chorób neurologicznych, onkologicznych i immunologicznych. Produkty firmy dotyczą chorób takich jak stwardnienie rozsiane, chłoniak nieziarniczy, reumatoidalne zapalenie stawów, choroba Crohna czy łuszczyca.

https://en.wikipedia.org/wiki/Biogen
https://www.biogen.com/
https://finviz.com/quote.ashx?t=BIIB
spółka nie płaci dywidendy

[slayer74]

ATechniczna - blisko wybicia górą z dwuletniego trendu bocznego

[slayer74]

ATechniczna
http://www.mdm.pl/ui-pub/site/analizy_i ... cid=902399

[slayer74]

Does Biogen Deserve More Credit for Q2 Earnings?
https://247wallst.com/healthcare-busine ... -earnings/

[slayer74]

Biogen Tumbles Despite Successful Test For Alzheimer's Drug
https://www.investors.com/news/technolo ... s-disease/

[slayer74]

Biogen Crushes Third-Quarter Earnings Views As Sales Also Top
https://www.investors.com/news/technolo ... -earnings/

[slayer74]

Biogen Rises on Strong Second-Quarter Earnings, Guidance Boost

Shares of drugmaker Biogen (BIIB - Get Report) rose in premarket trading Tuesday after the company reported second-quarter results that beat analysts' forecasts, and also raised its guidance for the remainder of the year on strong demand for its multiple sclerosis and other disease-fighting medications.

Biogen posted GAAP net income of $1.49 billion, or $7.85 a share, vs. $866.6 million, or $4.18 a share, in the comparable year-earlier quarter. Analysts polled by FactSet had been expecting earnings of $7.45 a share. Revenue was $3.61 billion vs. $3.36 billion a year earlier, and above analysts' estimates of $3.48 billion.

The company also lifted its full-year outlook. For 2019, the company raised its adjusted per-share earnings outlook to between $31.50 and $32.30 from between $28 and $29, and its revenue guidance to between $14 billion and $14.2 billion from between $13.6 billion and $13.8 billion.

Multiple sclerosis revenue rose 3% to $2.4 billion, as Tecfidera sales increased 6% to $1.15 billion, the company said. Spinraza sales increased to $488 million from $423 million.
https://www.thestreet.com/investing/ear ... s-15028271

[slayer74]

Why Biogen’s Q2 Was So Great
https://247wallst.com/healthcare-busine ... -so-great/

[slayer74]

Biogen stock fell Wednesday after the biotech company reported adjusted earnings of $9.14 per share on $3.53 in sales for its first quarter.

On average, analysts polled by Zacks Investment Research expected Biogen (BIIB) to earn $7.74 a share on $3.42 billion in sales.

In the year-earlier period, Biogen earnings were $6.98 per share on $3.49 billion in sales.

Biogen didn't provide any guidance in the earnings release The Street projected adjusted profit of $32.45 per share and $14.13 billion in sales.

https://www.investors.com/news/technolo ... s-q1-2020/

[slayer74]

Biogen stock rose early Wednesday after the biotech company reported adjusted earnings of $10.26 per share on $3.68 billion in sales for its second quarter.

On average, analysts polled by Zacks Investment Research expected Biogen (BIIB) to earn $7.99 per share on $3.43 billion in sales.

In the year-earlier period, Biogen reported adjusted income of $9.15 a share and $3.62 billion in sales.

For the year, Biogen raised its adjusted EPS target to $34.00-$36.00 from $31.50-$33.50. But it trimmed its 2020 revenue range to $13.8 billion-14.2 billion from $14 billion to $14.3 billion. Analysts projected $33.19 in earnings per share and $13.98 billion in sales.

https://www.investors.com/news/technolo ... s-q2-2020/

[slayer74]

Biogen-Eisai Alzheimer's Drug Gets FDA Priority Review

https://www.thestreet.com/investing/bio ... ity-review

[slayer74]

Biogen (NASDAQ:BIIB) stock fell 3.9% after the biotech company said its profit came in below expectations for the latest quarter as revenue declined as it spent more on research and development.

[slayer74]

First patient receives controversial Biogen Alzheimer's drug

https://www.investing.com/news/stock-ma ... ug-2533624

[slayer74]

Biogen (BIIB) tumbled after the
Cleveland Clinic, Mount Sinai
Health System and Providence
said they wouldn’t administer its
controversial Alzheimer’s treatment, Aduhelm. The Cleveland
Clinic cited questions on safety
and effectiveness. Mount Sinai
noted a pending investigation by
the Office of Inspector General.

[slayer74]

Biogen (BIIB) sank 7% in heavy trade to a three-month low. It's on pace to extend its losing streak to seven. The stock undercut its 50-day line last week, after two House Democrats requested additional information regarding the Food and Drug Administration's approval of Biogen's Alzheimer's drug Aduhelm.